Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FDD79
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,284
Award facts
- Contract value 100% obligated
- $9,284.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $9,284.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The award, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036.
The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors capable of supplying comprehensive pharmaceutical products to support Department of Defense military healthcare operations worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders for diverse product lines—including oncology treatments, immunosuppressants, biologics, vaccines, and specialty pharmaceuticals—positions the company as a critical pharmaceutical supplier within the federal military medical supply chain. The contractor operates without identified subcontractors and maintains consistent performance as a sole source of supply under this indefinite delivery vehicle, enabling the Defense Logistics Agency to efficiently procure specialized pharmaceutical products including Xolair for military healthcare facilities.
Quick answers
Who was awarded contract SPE2DB26FDD79?
SPE2DB26FDD79 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FDD79 worth?
The government has obligated $9,284 on SPE2DB26FDD79.
Is contract SPE2DB26FDD79 an order under another contract?
Yes. SPE2DB26FDD79 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB26FDD79 competed?
The extent of competition for SPE2DB26FDD79 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award